Genfit
Clinical trials sponsored by Genfit, explained in plain language.
A biopharmaceutical company developing treatments for liver diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental drug aims to halt liver failure in cirrhosis patients Results expected Aug 2027 (estimated)
-
Experimental liver drug shows early promise but trial cut short
Disease control Stopped earlyThis early study tested a drug called VS-01 in 15 adults with acute-on-chronic liver failure (a sudden worsening of liver function) and fluid buildup in the belly. Participants received either VS-01 plus standard care or standard care alone. The trial was terminated early, so we …
Phase 2 • Sponsor: Genfit • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Liver drug trial halted after just 3 patients
Disease control Stopped earlyThis study tested a drug called VS-01 for people with severe confusion caused by liver disease (overt hepatic encephalopathy). The trial planned to enroll many participants but was stopped early after only 3 people joined. Researchers wanted to see if VS-01 could help patients re…
Phase 2 • Sponsor: Genfit • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC